A lymphangiogram is a type of X-ray taken of the lymphatic system using a special contrast agent to enhance the image. The invention of the CT scan, the gallium scan, the MRI and the PET scan have rendered this method of diagnosis obsolete.
The lymphangiogram starts when the technician numbs the patient's foot. A small incision is made between the toes and the contrast agent, or "dye", is injected into the lymph system. The dye travels up the leg and into the lymph vessels of the groin and abdomen. X-rays are then taken.
Patients should be aware that the dye might be uncomfortable and cause a mild burning sensation. The vessels of the foot may also turn visibly blue, as that is the color of the dye.
After the X-rays are taken, the incision is closed. Dressings should be properly applied so that the cut stays clean. Patients may have blue or green colored urine in the days following the scan, but this is not a bad sign.
The dye will last from 6 months to 2 years, which means that repeated X-rays can be taken to monitor lymphoma without repeating the full procedure.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...